Loading…
CPIX
Cumberland Pharmaceuticals Inc
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 230770109
$8.46-2.20%Price as of Aug 29, 18:34 UTC · updated once a day, after the close
Key metrics
- Market cap
- $126.76M
- P/E
- —
- Forward P/E
- 60.4x
- P/B
- 7.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.21
- ROE
- -14.39%
- Profit margin
- -24.64%
- Revenue growth
- -56.30%
- Beta
- 0.11
- 52-week high
- $9.28
- 52-week low
- $1.85
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +182.9% over 5Y.
today you would have $3,661.82▲ +266.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.98 | $2.37 | $1.79 | $2.25 | $4.67 | $2.95 | $5.15 | $6.03 | $7.36 | $5.50 | $5.26 | $5.98 | $5.11 | $4.20 | $5.38 | $5.99 | $13.59 | |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$5.71
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$1.62
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AARDAardvark Therapeutics, Inc. | $5.79 | — | 1.7x | — | -66.02% | $126.71M |
| CBUSCibus, Inc. | $1.65 | — | 8.5x | — | -223.16% | $126.11M |
| BDTXBlack Diamond Therapeutics, Inc. | $2.23 | — | 1.3x | — | -37.22% | $127.78M |
| VTVTvTv Therapeutics Inc. | $32.36 |
About the company
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
- 88
- Nashville, United States
Company description provided by Yahoo Finance.